RareCyte® announced today the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company’s new Orion spatial biology platform
RareCyte® announces a new rare cell detection kit, The Cell Discovery Kit, which enables custom panel development in your lab for the detection of circulating tumor cells (CTCs) that do not express epithelial markers
Upcoming webinar on 02 Dec – Multiplexed Tissue Imaging using the Orion Platform to Reveal the Spatial Biology of Cancer. Join Dr. Sandro Santagata from Brigham and Women’s Hospital as he discusses the use of multiplexed antibody-based tissue imaging of multiple antigens at single cell resolution using both cyclic immunofluorescence (CyCIF) and Orion high-plex imaging.
“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”
– Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company